ClinicalTrials.gg
RecruitingNCT06210854Updated Jul 1, 2026

Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+

A Phase 2 interventional study of pBI-11 (3 doses) and pBI-11 (1 dose) in HPV Infection, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.

Planned enrollment
98th of 132
48 · median 128
Started
2026
with 7 others
Phase 2
43 of 166
10 open now
Primary completion
2028-11
later than 49 of 59 live
Registered
137th of 166
by date

Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 98th largest by planned enrollment of the 132 interventional ones that give a count, is one of 8 that started in 2026, is one of 43 in phase 2, reaches primary completion later than 49 of the 59 other live ones, and was the 137th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Papillomavirus Infections with a site in United States, or all of them as a file.
02

Study summary

This research is being done to test the safety and feasibility of an investigational DNA vaccine called pBI-11 and to find out what effects, if any, it has on women with persistent human papillomavirus 16 (HPV16+) and/or human papillomavirus (HPV18+) cervical infection.

The DNA vaccine is designed to promote an immune response to treat disease caused by HPV types 16 and 18, viruses that can cause cervical cancer. The pBI-11 DNA vaccine or a placebo will be administered intramuscularly using the TriGridTM Delivery System.

Read the detailed description

This is a randomized double-blind placebo-controlled phase II study with cross-over design. The primary goal of this study is three-fold; one is to determine the safety and feasibility of two pBI-11 DNA administrations four weeks apart in patients with persistent HPV16 and/or HPV18+ \<CIN2, wherein 3.0 mg of the plasmid DNA is delivered via electroporation mediated intramuscular (IM) administration with the TriGrid Delivery System version 2.0 (TDS-IM v2.0); to evaluate the effect of vaccine on HPV16/18 viral DNA clearance; to evaluate the reliability of the device.

03

Conditions studied

  • HPV Infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Negative for Intraepithelial Lesions (NEIL), Atypical Squamous Cells of Undetermined Significance (ASC-US), or Low-grade Squamous Intraepithelial Lesion (LSIL) determined by cervical cytology

AND

  • HPV16 and/or 18+ by Roche Cobas 4800, Roche Linear Array HPV Genotyping test, or other FDA-approved HPV genotyping test (Co-infections with HPV types other than HPV16/18 are permissible).
  • Age ≥ 18 years
  • Baseline performance status of 0 or 1 at the time of enrollment.
  • Patients must have adequate organ function at the time of enrollment as defined by the following parameters:
  • White blood cell count ≥ 3,000 cells/uL
  • Absolute lymphocyte number ≥ 500 cells/uL
  • ≥ 1,500 cells/uL
  • ≥ 90,000 cells/uL
  • Hemoglobulin ≥ 9 g/dL
  • Total \< 3 X the institutional limit of normal
  • (AST) and Alanine Aminotransferase(ALT) \< 3 X the institutional limit of normal
  • Creatinine \< 2.5 X the institutional limit of normal
  • Women of must agree to use long acting (e.g. tubal ligation, intrauterine device or hormonal implant) or two forms of contraception (e.g. barrier method, oral contraceptives) prior to study entry and for 3 months after final vaccination.
  • Ability to understand and the willingness to sign a written document.
  • Able to adhere to the study visit schedule and other protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Histologic evidence of CIN2, cervical intraepithelial neoplasia 3 (CIN3), adenocarcinoma in situ or .
  • Patients with a diagnosis of or active systemic use of immunosuppressive medications such as .
  • Patients who are receiving any other agents within 28 days prior to the first dose of study vaccine.
  • Patients with an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Patients with a history of systemic disease such as multiple sclerosis or systemic lupus erythematosus (SLE), but exclusive of a history of thyroiditis, psoriasis, Sjogren's, or inflammatory bowel disease.
  • Patients who are pregnant or breast feeding or plan to become pregnant within 12 months of first study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to pBI-11 DNA vaccine.
  • Patient with active infection of, or receiving treatment for (HIV), Virus (HCV), or Virus (HBV).
  • History of prior malignancy with disease free interval \<5 years; however, individuals with completely resected basal cell or squamous cell carcinoma of the skin within this interval may be enrolled.
  • Participants with metal implant(s) at the site of injection or any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators.
  • Participants with any chronic or active neurologic disorder, including seizures and epilepsy, excluding a single febrile seizure as a child or episode of seizure in pregnancy due to eclampsia.
  • Participants with syncopal episode within 12 months of screening, excluding fainting for a known and unrelated cause such as anemia which has been resolved.
  • Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period.
  • Participants with a skin-fold measurement of the cutaneous and subcutaneous tissue for all eligible injection sites (vastus lateralis muscles with intact lymph drainage) exceeds 50 mm.
  • Participants in whom the ability to observe possible local reactions at the injection site (lateralis region) is, in the opinion of the investigator, unacceptably obscured due to a physical condition or permanent body art.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm 1: pBI-11 + pBI-11 + pBI-11

    Will receive 3 doses of pBI-11 using the TriGrid Delivery System.

    Biological: pBI-11 (3 doses)

  • Experimental
    Arm 2: Placebo + Placebo + pBI-11

    Will receive 2 doses of placebo and 1 dose of pBI-11 using the TriGrid Delivery System

    Biological: pBI-11 (1 dose) · Biological: Placebo (2 doses)

Interventions

  • BiologicalpBI-11 (3 doses)

    pBI-11 at Day 0, Week 4, Month 7

    Also known as: pBI-11 plasmid DNA

  • BiologicalpBI-11 (1 dose)

    pBI-11 at Month 7

  • BiologicalPlacebo (2 doses)

    Placebo (saline) vaccine at Day 0, Week 4

06

What researchers measure

Primary outcomes

  1. Safety - Frequency and Severity Local Adverse Events and Abnormalities

    Count of the frequency and severity of local adverse events and abnormalities per CTCAE 5.0

    Time frame: Post-first study vaccination up to 12 months

  2. Safety - Frequency and Severity Systemic Adverse Events and Abnormalities

    Count of the frequency and severity of systemic adverse events and abnormalities per CTCAE 5.0

    Time frame: Post-first study vaccination up to 12 months

  3. Safety - Frequency and Severity Solicited Local Adverse Events and Abnormalities

    Count of the frequency and severity of solicited local adverse events and abnormalities per CTCAE 5.0

    Time frame: Through 7 days after each study vaccine

  4. Safety - Frequency and Severity Solicited Systemic Adverse Events and Abnormalities

    Count of the frequency and severity of solicited systemic adverse events and abnormalities per CTCAE 5.0.

    Time frame: At Week 0 up to 7 days post vaccine, At week 4 up to 7 days post vaccine, At 7 months up to 7 days post vaccine

  5. Pain Scores assessed by Visual Analog Scale

    The mean and standard deviation of the visual analog scale (VAS) based pain scores reported by the participants on the tolerability questionnaire. Scale range 0-10 with higher scores indicating worse pain.

    Time frame: Week 0, Week 4, 7 months

  6. Acceptability as assessed by survey

    The percentage of "Yes" responses to the acceptability question posed in the tolerability questionnaire

    Time frame: Week 0, Week 4, 7 months

  7. Percentage of participants with no HPV16/18 detection

    Effect of 2 doses of pBI-11 on HPV16/18 clearance. The percentage of participants with no detection of HPV16 or HPV18 in cervical specimens by Roche Cobas test.

    Time frame: At 6 months post first study vaccine

  8. Reliability - Percentage of Device Faults

    Percentage of administration procedures where a device fault is observed.

    Time frame: Duration of study, approximately 12 months

  9. Reliability -Percentage of Delays

    Percentage of administration procedures during which a device fault results in a delay in completion of the administration procedure of \> 15 minutes.

    Time frame: Duration of study, approximately 12 months

Secondary outcomes

  1. Effect of 3 doses of pBI-11 on HPV16/18 clearance - Percentage of Participants that Exhibit HPV16/18 Positivity (Active arm)

    The percentage of participants in the active arm that exhibit HPV16/18 positivity by Roche Cobas test

    Time frame: At Month 12 post first study vaccine

  2. Effect of 1 dose of pBI-11 on HPV16/18 clearance - Percentage of participants that exhibit HPV16/18 positivity (Placebo arm)

    The percentage of participants in the placebo arm that exhibit HPV16/18 positivity by Roche Cobas test

    Time frame: At Month 12 post first study vaccine

  3. Levels of HPV16/18 E6/E7-specific T cells

    Magnitude of HPV16/18 E6, and E7 cellular immune responses as assessed by interferon-gamma ELISpot, relative to baseline sample

    Time frame: At Week 8 post first study vaccine

  4. Changes in Cytopathology

    Changes in cytopathology of specimens taken pre- and post-vaccination by each regimen

    Time frame: Baseline, 6 months, and 12 months post-first study vaccine

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2028, 29 months after the start.

Of 41 phase 2 interventional studies under Papillomavirus Infections, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 77. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2024
First posted
Jan 18, 2024
StartActual
Jun 25, 2026
Primary completionEst.
Nov 2028
CompletionEst.
May 2029
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06210854
Collaborators
PapiVax Biotech, Inc., National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Jan 18, 2024
Start date
Jun 25, 2026
Primary completion
Nov 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Jul 1, 2026

Study contacts

Kimberly Levinson, MD
Contact
klevins1@jhmi.edu
410-955-8240
Kimberly Levinson, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion